Disc Medicine, INC 10-Q quarterly reports

Disc Medicine, Inc. reported its financial results for the second quarter of 2026, highlighting progress in its hematologic disease pipeline and providing an update on its bitopertin program.

Disc Medicine Inc. reported its Q1 2026 financial results, highlighting increased R&D expenses and providing an update on the bitopertin New Drug Application (NDA) status.

Disc Medicine reports increased losses but a strong cash position into 2029, driven by a recent $210.9 million capital raise and accelerated FDA review for bitopertin in EPP and XLP.

Disc Medicine, a clinical-stage biopharmaceutical company, reported increased R&D expenses and net losses in Q2 2025, but maintains a strong cash position to fund operations into 2028, driven by progress in its hematologic disease pipeline and a planned October 2025 NDA submission for bitopertin.

Disc Medicine reports a net loss of $34.1 million for Q1 2025 while advancing its clinical programs and maintaining a strong cash position.

Disc Medicine, a clinical-stage biopharmaceutical company, released its third-quarter 2024 results, highlighting progress in its hematologic disease programs and financial position.

Disc Medicine, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and recent capital raising activities.

Disc Medicine, a clinical-stage biopharmaceutical company, announced its first quarter 2024 financial results, highlighting ongoing clinical trials and research and development activities.